Relmada Therapeutics (RLMD) Long-Term Debt Repayments (2014 - 2020)
Relmada Therapeutics (RLMD) reported Long-Term Debt Repayments of $110247.0 for Q1 2020, up 28.24% year-over-year from $85969.0 in Q2 2019, and down 56.59% quarter-over-quarter from $253957.0 in Q4 2019.
Relmada Therapeutics (RLMD) Long-Term Debt Repayments (2014 - 2020) Analysis & Trends
Relmada Therapeutics (RLMD) has 7 years of Long-Term Debt Repayments data on file, last reported at $110247.0 in Q1 2020.
- Long-Term Debt Repayments for Q1 2020 came in at $110247.0, up 28.24% year-over-year; the trailing twelve-month figure through Dec 2020 was $110247.0 (down 77.25% YoY), and the FY2022 annual result was $50000.0, changed N/A from the prior year.
- Long-Term Debt Repayments fell to $110247.0 in Q1 2020 per RLMD's latest filing, from $253957.0 in the prior quarter.
- Over five years, Long-Term Debt Repayments peaked at $253957.0 in Q4 2019 and troughed at $27583.0 in Q2 2017.
- A 5-year average of $91750.5 and a median of $84966.0 in 2018 frame the typical range for Long-Term Debt Repayments.
- The sharpest annual moves came in 2016 and 2019: Long-Term Debt Repayments plunged 38.12% in 2016, then surged 197.14% in 2019.
- A 5-year view of Long-Term Debt Repayments shows it stood at $54403.0 in 2016, then jumped by 52.43% to $82929.0 in 2017, then gained by 3.06% to $85466.0 in 2018, then surged by 197.14% to $253957.0 in 2019, then sank by 56.59% to $110247.0 in 2020.
- Business Quant data shows RLMD's Long-Term Debt Repayments at $110247.0 in Q1 2020, $253957.0 in Q4 2019, and $108279.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 110,247.00 |
| Mar 31, 2020 | 110,247.00 |
| Dec 31, 2019 | 253,957.00 |
| Dec 31, 2019 | 253,957.00 |
| Sep 30, 2019 | 108,279.00 |
| Sep 30, 2019 | 108,279.00 |
| Jun 30, 2019 | 36,380.00 |
| Jun 30, 2019 | 36,380.00 |
| Mar 31, 2019 | 85,969.00 |
| Mar 31, 2019 | 85,969.00 |
| Dec 31, 2018 | 85,466.00 |
| Dec 31, 2018 | 85,466.00 |
| Sep 30, 2018 | 84,966.00 |
| Sep 30, 2018 | 84,966.00 |
| Mar 31, 2018 | 83,355.00 |
| Mar 31, 2018 | 83,355.00 |
| Dec 31, 2017 | 82,929.00 |
| Dec 31, 2017 | 82,929.00 |
| Sep 30, 2017 | 82,506.00 |
| Sep 30, 2017 | 82,506.00 |